REMARKS

Amendment to claims 2 and 9

Claims 2 and 9 are amended to correct the definition of R^3 and thereby bring the claims into conformity with the original disclosure. Preliminary Amendment A was filed in the subject application on January 3, 2002, the purpose of which was to provide chemical names for trademarks or trade names appearing in the application. In that preliminary amendment, the marked-up and clean copies of claims 2 and 9 inadvertently omitted four substituents from the definition of R^3 in those claims: cycloalkyl, aryl, haloalkyl, and heterocyclyl. These substituents are disclosed in the specification and original claims, see page 5, lines 31-32 of the specification; original claim 2, lines 30-31; and original claim 9, lines 18-19. Thus, no new matter is added by this amendment.

Election of species

In response to the Examiner's request to elect a single disclosed species, and pursuant to MPEP § 809.02(a), Applicants hereby elect the species wherein the cyclooxygenase-2 inhibitor is 4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl-1H-pyrazol-1-yl] benzenesulfonamide (i.e., a compound of Formula I wherein A is an unsaturated heterocyclyl, R^1 is aryl substituted with halo and alkoxy, R^2 is amino and R^3 is haloalkyl; this compound is shown in Example 2) and the leukotriene B_4 receptor antagonist is Searle SC-53228 (2H-1-Benzopyran-2-propanoic acid, 7-[3-[2-(cyclopropylmethyl)-3-methoxy-4-[(methylamino)carbonyl]phenoxy] propoxy]-3,4-dihydro-8-propyl-, (2S)) (i.e., Example 3). Claims 1-4 and 6-9 read on the elected species.

According to MPEP § 809.02(c), an Examiner's action subsequent to an election of species should include a complete action on the merits of all claims readable on the elected species and according to MPEP § 809.02(e), whenever a generic claim is found to be allowable in substance, action on the species claims shall thereupon be given as if the generic claim

were allowed. Thus, if it is determined that the elected species is patentable, it is incumbent upon the Office to search additional species that fall within any allowable generic claims.

VERSION WITH MARKINGS SHOWING CHANGES MADE

Claim 2 has been amended as follows:

2. (twice amended) A combination comprising a therapeutically-effective amount of a leukotriene B_4 receptor antagonist and a cyclooxygenase-2 inhibitor selected from Taisho NS-398 (Methanesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]), meloxicam (2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide), flosulide (Methanesulfonamide, N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]), Merck MK-966 (2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl), Merck L-752,860 and compounds of Formula I



wherein A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

wherein R^1 is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R^1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsufinyl, halo, alkoxy and alkylthio;

wherein R^2 is methyl or amino; and

wherein R^3 is a radical selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, **cycloalkyl, aryl, haloalkyl, heterocyclyl,** cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl,

aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl;

or a pharmaceutically-acceptable salt thereof.

Claim 9 has been amended as follows:

9. (twice amended) A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically-effective amount of a leukotriene B_4 receptor antagonist and a cyclooxygenase-2 inhibitor selected from Taisho NS-398 (Methanesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]), meloxicam (2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide), flosulide (Methanesulfonamide, N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]), Merck MK-966 (2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl), Merck L-752,860 and compounds of Formula I



wherein A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings;

wherein R^1 is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R^1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino,

alkylamino, arylamino, nitro, alkoxyalkyl, alkylsufinyl, halo, alkoxy and alkylthio;

wherein R^2 is methyl or amino; and

wherein R^3 is a radical selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, **cycloalkyl, aryl, haloalkyl, heterocyclyl,** cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N-alkyl-N-arylaminosulfonyl;

or a pharmaceutically-acceptable salt thereof.

If there are any additional charges in this matter, please charge Deposit Account No. 19-1345.

Respectfully submitted,



Edward J. Hejlek, Reg. No. 31,525
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

EJH/PKF/rle

Express Mail Label No. EL 945485771 US